Please login to the form below

Not currently logged in
Email:
Password:

lipegfilgrastim

This page shows the latest lipegfilgrastim news and features for those working in and with pharma, biotech and healthcare.

Teva withdraws US filing for cancer biologic

Teva withdraws US filing for cancer biologic

There was better news for Teva's G-CSF portfolio however after it launched its long-acting G-CSF product Lonquex (lipegfilgrastim) on November 4 in Germany, the first EU market

Latest news

  • Neulasta rival from Teva cleared in EU Neulasta rival from Teva cleared in EU

    Lonquex (lipegfilgrastim) has been approved to reduce the duration of neutropaenia (low white blood cell counts) and febrile neutropaenia in patients undergoing cytotoxic chemotherapy for cancer, and is given as a ... which like lipegfilgrastim is

  • EMA backs Pomalidomide Celgene in multiple myeloma EMA backs Pomalidomide Celgene in multiple myeloma

    Elsewhere, there were further recommendations for Teva's (Lonquex) lipegfilgrastim, which was recommended for the reduction in white blood cells of cancer patients on chemotherapy; Bavarian Nordic's smallpox vaccine Imnavex;

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics